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Background: Acute bronchitis, frequently emerging with the common cold is one of the most frequent causes of
primary care consultations. It is a self-limiting disease which poses both high symptom burden to individuals and
high financial burden to society. It is largely a viral disease (~50 % rhinovirus infection), but no causal (antiviral)
treatment exists. Antibiotics, mucoactive agents, antihistamines, antitussives, decongestants are most often used but
without evidence from randomized controlled trials (RCT) for relieving symptoms or fostering recovery.
Many in vitro and ex vivo studies with standardized herbal extracts did show important effects on inflammatory
mediators, mucus hypersecretion, cough and bronchospasm. Moreover, several successful clinical RCT’s with unique
herbal compounds were published, many other are ongoing.
Methods: Preliminary medline search for randomized controlled studies with herbal medicine for bronchitis.
Results: Eighteen studies were found fulfilling search criteria; six were excluded due to duplicate publication, active
comparator control or open design. In 2015 German cough guidelines (in preparation) at least 12 studies will
provide evidence for developing recommendations for treatment of acute bronchitis.
Conclusions: In conclusion, several herbal compounds achieved as first pharmaco-therapeutic remedies at all
evidence for treatment of acute bronchitis/common cold. Evidence based guidelines are starting to include
recommendations for treatment of acute bronchitis/common cold with dedicated phytomedicine.
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Acute bronchitis is an inflammatory disease of the tra-
cheobronchial system, clinically characterized by cough
with or without sputum production. In their New England
Journal review Wenzel et al. define: “Acute bronchitis is a
clinical term implying a self-limited inflammation of the
large airways of the lung that is characterized by cough
without pneumonia.”[1]. However, according to the
American College of Chest Physician guidelines acute
cough is also one of the main symptoms of common cold:
…the clinical syndrome of nasal congestion, nasal dis-
charge, postnasal drip (PND), throat clearing, sneezing,
and cough is common to all of these infections.” [2]. It is
largely recognized that distinguishing between acute
cough due to acute bronchitis and/or common cold is not
practicable: “The prevalence of cough due to the commonCorrespondence: Kardos@lungenpraxis-maingau.de
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the original work is properly credited.cold is as high as 83 % within the first two days of illness
and because the common cold and acute bronchitis share
many of the same symptoms the clinical distinction be-
tween acute and chronic bronchitis and the common cold
is difficult, or at times, impossible to make.”[3]. This prob-
lem is well recognized not only in guidelines, but also in
clinical papers [4] and RCT reports [5].
Indeed, in a retrospective study Hueston et al. investi-
gated how to best distinguish between acute bronchitis
and common cold and concluded: “…there was consider-
able overlap between the 2 conditions, and the logistic
model explained only 37 % of the variation between the
diagnoses. Conclusions: We hypothesize that sinusitis,
URI, and acute bronchitis are all variations of the same
clinical condition (acute respiratory infection)…” [6].
“Acute bronchitis is one of the most common reasons for
patient visits to ambulatory care or physicians. Frequently,
it develops during the course of a common cold with a pre-
dominant symptom of dry or productive cough.” [5].istributed under the terms of the Creative Commons Attribution License (http://
ermits unrestricted use, distribution, and reproduction in any medium, provided
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limiting disease with an average duration of the main symp-
tom cough of 14 days [4]. In children, however acute cough
can last an average of 25 days [7]. Nonetheless, cough
guidelines [8–10] define acute cough lasting as long as up
to eight weeks – under some circumstances, i.e., if elicited
by adenovirus, mycoplasma pneumoniae or Bordatella per-
tussis infection. Some people are using the definition of
subacute cough [11], lasting 3–8 weeks.
After eight weeks of duration, cough/bronchitis will be
defined as chronic. In contrast to acute bronchitis beyond
history and clinical exam further diagnostic measures (i.e.,
chest x-ray and spirometry) are considered necessary in
chronic bronchitis .
Acute bronchitis, caused largely by viruses (~50 % rhino-
virus infection), no causal (antiviral) treatment exists. Des-
pite being a self limiting disease, acute bronchitis poses
both a high symptom burden to individuals and a high fi-
nancial burden to society, mainly due to work and school
absenteeism. Moreover, in the community, up to 85 % of
cases of acute bronchitis are treated with antibiotics – with
little impact on recovery [12]. Unnecessary and uncon-
trolled use of antibiotics in acute bronchitis contributes to
an impending doom of antibiotic resistance [13].
As yet no RCT based evidence exists for synthetic
drugs as opposed to herbal compounds for acute bron-
chitis. Yet, in randomized controlled trials (RCT’s)
largely used older, patent-free synthetic substances i.e.,
muco-active drugs, antitussives, antihistamines, NSAR
(non-steroidal anti-rheumatics) with a distinct straight-
forward pathophysiological target do not have proven
clinical benefit vs. placebo [14].
Six thousand years B.C. the old Egyptians already used
plants to treat ailments, thus many centuries empirical
knowledge was collected on use of herbal remedies. As yet,
the majority of phytotherapeutics in use in the European
community is approved merely based on such empirical
knowledge. At the very end of the XX. century however, in
medicine evidence based scientific guidelines were intro-
duced and new approvals request scientific evidence of effi-
cacy. There are different tools in use for assessment of
evidence and for generating recommendations, but all those
systems require controlled trials to show efficacy against
placebo or at least a proven comparator drug. For evidence
based recommendation (and for approval) adverse events
and real world effectiveness are also taken into account.
But popularity and low rates of adverse events are not suffi-
cient for guideline recommendations.
Recently some standardized herbal extracts in RCT’s
were proven effective against placebo relieving symptom
burden and fostering recovery in acute bronchitis. (An-
other field of phytotherapy in bronchitis - beyond the
scope of this article - is the prevention of exacerbations of
chronic obstructive lung disease (COPD) on top ofguideline based treatments beside long acting bronchodi-
lators and inhaled corticosteroids).
This article shall define the evidence base of some
herbal therapeutics in the treatment of acute bronchitis.
Guidelines on cough
The first German evidence based guidelines for cough
were published 2004 [15]. At that time, literature search
could not reveal randomized controlled trials with accept-
able methodology for treatment of acute bronchitis [1].
Thus, no recommendation for pharmacological therapy
was given. This result was little surprising according to
many methodological pitfalls for RCT’s in acute bronchitis
(with or without common cold):
1. In a self-limiting disease (i.e., acute bronchitis) with
an average duration of the main symptom cough of
merely 14 days even effective treatments can only
reduce duration or severity of symptoms if timely
introduced.
2. many patients are not seeking medical attention,
limiting recruitment to RCT’s
3. Every pharmacotherapy of acute bronchitis has a
huge placebo effect [16]
4. In the past, no outcomes in acute bronchitis trials
were agreed upon
5. most if not all bronchitis remedies were available as
over the counter (OTC) generics. Hence, sponsoring
of sufficiently large clinical trials was not obtainable.
In 2010, an update of the German cough Guidelines was
published [8]. In 2009, the literature search identified
RCT’s showing efficacy shortening symptoms of acute
bronchitis for two herbal combinations [17, 18] graded as
moderate evidence leading to a strong recommendation
for treatment of acute bronchitis with the proven
combinations.
Methods and results
For the 2015 update of the German cough guidelines I
performed a preliminary search in medline for trials with
herbal medicine in acute bronchitis. In December 2014
using search terms (bronchitis AND herbal; bronchitis
AND phytomedicine; bronchitis AND phytotherapy; com-
mon cold AND herbal; common cold AND phytomedi-
cine; common cold AND phytotherapy) each in title and
abstract resulted in 185 hits, subtracting duplicate hits
remained 143 results. According to the abstracts in this
preliminary search about 18 controlled trials for acute
bronchitis outcomes were found. According to duplicate
publications of the same trial and active control noninferi-
ority trials we show in Table 1 the preliminary results with
12 studies [17–28]. Moreover, data from publication 25
were also separately published for Russian centres (26).
Table 1 Randomized controled trials with herbal medicine in acute bronchitis
Verum dosage form Author Year Age group Number
of patients
Primary outcome Result
GeloMyrtol® forte (capsules) Gillissen et al. [19] 2013 18-83
years
413 Mean change in coughing fits during daytime
according to patient´s diary from day 0 to day 7–9.
The mean change in coughing fits from day 0 to day 7–9 was
significantly higher for verum compared to placebo (p <0.0001)
showing superiority. 7.9 % of verum treated patients showed
AEs.
EPs 7630 * (drops) Kamin et al. [22] 2012 1-18 years 220 Change in total score of bronchitis severity score
(BSS) from day 0 to day 7
Decrease in BSS total score was significantly higher for verum
compared to placebo (p <0.0001). 1.8 % of verum treated
patients showed AEs.
EPs 7630 * (drops) Kamin et al. [21] 2010 1-18 years 200 Change in total score of BSS from day 0 to day 7 Decrease in BSS total score was significantly higher for verum
compared to placebo (p <0.0001). In 27.5 % of the patients AEs
occured.
EPs 7630 * (film-coated
tablets)
Kamin et al. [20] 2010 6-18 years 400 Dosage finding of EPs-7630 (30 mg, 60 mg, 90 mg)
and change in BSS total score from day 0 to day 7
rated by investigator
Change in BSS total score significantly better in 60 mg and
90 mg compared to placebo showing superiority. There were
no relevant differences between these two dosages. No
superiority was shown for 30 mg compared to placebo. In
19.3 % of the patients AEs occurred.
EPs 7630* (film-coated
tablets)
Matthys et al. [23] 2010 > 18 years 406 Dosage finding of EPs-7630 (30 mg, 60 mg, 90 mg)
and change in BSS total score from day 0 to day 7
The differences in the change of BSS between all groups of
verum treated patients and placebo treated patients was
significant (p <0.0001). Inferiority of 60 mg compared to 30 mg.
In 18.5 % of the patients AEs occurred.




217* Change in BSS from day 0 to day 7 BSS decreased significantly more in verum compared to
placebo (p <0.0001). In 21.3 % of verum treated patients AEs
occurred.
EPs 7630* (drops) Matthys and
Heger [25]
2007 > 18 years 205 Change in BSS from day 0 and day 7 The total score of BSS decreased from day 0 to day 7 with
verum compared to placebo showing superiority. In 7.8 % of
the patients AEs occurred.
EPs 7630* (drops?) Chuchalin et al.
[26]**
2005 > 18 years 124 Change in BSS from baseline to day 7 The decrease in BSS showed a significant decrease of verum
compared to placebo (p <0.0001). Adverse events occurred in
23 % of patients.
EPs 7630* (drops) Matthys et al. [27] 2003 > 18 years 468 Change in BSS from baseline to day 7 The decrease in BSS showed a significant superiority of verum
against placebo (p <0.0001). Adverse events occurred in 7.7 %
of the patients.
Fixed combination of dry
extracts of thyme herb and
primrose root (film-coated
tablets)
Kemmerich [17] 2007 18-85
years
361 Change in mean frequency of coughing fits during
daytime at day 7–9 compared to baseline
measured with a manual counter and recorded in
a patient diary
The mean reduction in coughing fits on days 7–9 compared to
baseline was significantly higher for verum compared to
placebo (p <0.0001) showing superiority. Adverse events
occurred in 1.7 % of the patients.
Fluid extract combination of






361 Change in mean frequency of coughing fits during
daytime at day 7–9 compared to baseline
measured with a manual counter and recorded in
a patient diary
The mean reduction in coughing fits on days 7–9 compared to
baseline was significantly higher for verum compared to
placebo (p <0.0001). Adverse events occurred in 4.1 % of the
patients.
Fixed combination of thyme
and primrose root (drops)
Gruenwald et al.
[28]
2005 > 18 years 150 Change in BSS at day 7–9 (end of treatment)
compared to baseline
Decrease of BSS was significantly higher for verum compared
to placebo. Adverse events occurred in 4.7 % of the patients.
*Pelargonium sidoides
**This data are also included in the publication #25 (double publication)
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in children in these studies: EPs7630, two different combi-
nations of thyme and primrose, one of thyme and ivy and
another of myrtol. I did not include many double-blind
non-inferiority active comparator controlled studies, if ef-
ficacy of “active control” was not proven, e.g., [29, 30]. All
(published) double-blind RCT’s showing significant effi-
cacy over placebo. However, publication bias cannot be
excluded. Final evidence tables with the 2015 update of
the guideline will be published later.
Nowadays getting RCT’s sponsored for herbal remedies
is feasible as the proven evidence is related not to a plant
or a combination of plants but only to the proven, unique
remedy (see dot 5 above). Efficacy of herbal compounds is
highly dependent on the plants used, extraction and
standardization methods. Results of clinical trials for a dis-
tinct preparation cannot be transferred for other prepara-
tions using the same plant or combination of plants.
Many patented herbal remedies are available for trials and
treatment. Moreover, for acute bronchitis/common cold, a
15 years old tool, BSS (bronchitis severity scale) is now a
validated outcome measure [31, 32]. Also recommenda-
tions for cough monitoring now exist [10]. Thus, in con-
trast to synthetic drugs, each herbal compound needs
independent RCT’s for proof of efficacy. For new ap-
provals EMA (European Medicine Agency) and FDA
(Food and Drug Administration) require replicate RCT’s.
Discussion
Even if common cold/acute bronchitis are self limiting
conditions, there is still a large unmet need for effective
therapy relieving patients symptoms and shortening the
course of disease with impact on the huge epidemio-
logical burden acute bronchitis posing on the society. In
contrast to many other frequent diseases i.e., coronary
heart disease, type 2 diabetes, tumors etc., common
cold/acute bronchitis affects mainly the young working
population.
As yet few pharmacotherapeutic options are evidence
based for the treatment of acute bronchitis, unless one ac-
knowledges the “evidence” that billions of euros and dollars
are spent for OTC drugs, i.e., expectorants, decongestants,
antitussives [33] without RCT-proven effects on the natural
history of the disease or symptoms. Moreover, the vast ma-
jority of patients with common cold/acute bronchitis con-
sulting a physician takes ineffective prescription antibiotics
for their viral disease resulting in a recent marked increase
in antibiotic resistance in the community.
Common cold/acute bronchitis is a complex inflam-
matory disease. Single pathomechanistic approaches to
treatment may be not effective. For example, even useful
antiviral treatment of influenza, a myxovirus infection,
with neuramidase blockers has limited activity on symp-
toms and is only effective if given in the first 48 h afteronset of fever. Current debate on the efficacy of oselta-
mivir shows how complex is conducting RCT’s in a self-
limiting viral disease [34]. Viral infections in common
cold (~50 % of those are due to rhinoviruses) of the re-
spiratory epithelium causes early release of many inflam-
matory mediators sensitizing chemosensitive cough
receptors. Moreover, epithelial shedding, leaving cough
receptors unprotected and vulnerable for even innocu-
ous inhalative physical stimuli such as changing
temperature, also enhances the cough reflex eliciting dry
cough.
Mucus hypersecretion by superficial goblet cells is re-
sponsible for wet cough, a characteristic of the first few
days of the viral infection. Mucociliary clearance is also
affected both by inflammatory cytokines and changes in
mucus viscosity. The inflammatory edema of the mucosa
causes paranasal sinus pain and/or increase in resistance
of the upper (nasal stuffiness) and lower airways. More-
over, in bronchial hyperresponsive patients, asthma
(bronchospasm) can be exacerbated.
Beyond systemic corticosteroids with broad anti-
inflammatory effects no single synthetic drug is known hav-
ing an effect on most patho- physiological components as
shown above. In contrast, in a myriad of in vitro and ex
vitro studies, important effects on several components of
the pathophysiology by single and composite herbal ex-
tracts are published, e.g., [35–44]. It is beyond the scope of
this article to discuss their results. Importantly, those
basic results generate hypotheses for clinical trials of herbal
drugs for common cold/acute bronchitis.Conclusion
As yet, very few evidence based treatments for one of the
the most frequent illnesses, common cold/acute bron-
chitis are available. High symptom and societal burden
justify intensive research for new evidence based effective
pharmacotherapies for this self-limiting disease with
multifaceted pathophysiology. High quality, standardized
herbal compounds with their broad pharmacologic effects
are probably the most promising approach to treat com-
mon cold. In the near future sophisticated cultivating of
eligible plants and extraction/standardization methods
(bioengineering) will allow production of targeted phy-
totherapeutics. In fact, several RCT-proven compounds
are already available. Phytopharmaca are generally well
tolerated and highly accepted by patients. Phytopharmaca
are also promising in broadening indication (e.g., subacute
cough, postviral rhinosinusitis) or even prevention of
COPD exacerbations.Abbreviations
COPD: Chronic obstructive lung disease; EMA: European Medicine Agency;
FDA: Food and drug administration (USA); RCT: Randomized controlled trial.
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